Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy

Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer

(2009) Siân Lennon et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study

(2009) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum HER-2/neuand relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

(2008) Suhail M. Ali et al.   CANCER

Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor

(2008) L. Witters et al.   CANCER RESEARCH

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer

(2008) David A Cameron et al.   Nature clinical practice. Oncology